Flavopiridol对胃肠道间质瘤细胞GIST882增殖、侵袭、凋亡及细胞周期的影响(4)
[13] Gao J，Tian Y，Li J，et al.Secondarymutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors[J].Medi Oncol，2013，30(2)：1-7.
[14] Antonescu C R，Besmer P，Guo T，et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation[J].Clin Cancer Res，2005，11(11)：4182-4190.
[15] Otto T，Sicinski P.Cell cycle proteins as promising targets in cancer therapy[J].Nat Rev Cancer，2017，17(2)：93-115.
[16] Di G C，Novellino E，Chilin A，Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer：an update on recent findings(2013-2016)[J].Expert Opin Investig Drugs，2016，25(10)：1215-1230.
[17] Roskoski R.Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs[J].Pharmacol Res，2016，107：249-275.
[18] Ang C，O’Reilly E M，Carvajal R D，et al.A nonrandomized，phase Ⅱ study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma[J].Gastrointest Cancer Res，2012，5(6)：185-189.
[19]宋悅，沈铿，徐峰.靶向调控的活性半胱氨酸天冬氨酸蛋白酶3联合细胞周期蛋白依赖性激酶抑制剂flavopiridol对卵巢上皮性癌的治疗作用[J].中华妇产科杂志，2010，45(10)：781-786.
[20] Zeidner J F，Karp J E.Clinical activity of alvocidib(flavopiridol) in acute myeloid leukemia[J].Leuk Res，2015，39(12)：1312-1318., http://www.100md.com(牛丽霞 郑绘霞 梁建芳 肖虹)
[14] Antonescu C R，Besmer P，Guo T，et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation[J].Clin Cancer Res，2005，11(11)：4182-4190.
[15] Otto T，Sicinski P.Cell cycle proteins as promising targets in cancer therapy[J].Nat Rev Cancer，2017，17(2)：93-115.
[16] Di G C，Novellino E，Chilin A，Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer：an update on recent findings(2013-2016)[J].Expert Opin Investig Drugs，2016，25(10)：1215-1230.
[17] Roskoski R.Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs[J].Pharmacol Res，2016，107：249-275.
[18] Ang C，O’Reilly E M，Carvajal R D，et al.A nonrandomized，phase Ⅱ study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma[J].Gastrointest Cancer Res，2012，5(6)：185-189.
[19]宋悅，沈铿，徐峰.靶向调控的活性半胱氨酸天冬氨酸蛋白酶3联合细胞周期蛋白依赖性激酶抑制剂flavopiridol对卵巢上皮性癌的治疗作用[J].中华妇产科杂志，2010，45(10)：781-786.
[20] Zeidner J F，Karp J E.Clinical activity of alvocidib(flavopiridol) in acute myeloid leukemia[J].Leuk Res，2015，39(12)：1312-1318., http://www.100md.com(牛丽霞 郑绘霞 梁建芳 肖虹)